Neuroinflammation Modulation Therapies for Neurodegenerative Diseases

Migration, Crosslink

📖

Neuroinflammation Modulation Therapies for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-neuroinflammation-modu

📖 Wiki Page

therapeutic1681 wordssynced 2026-04-02

Neuroinflammation Modulation Therapies for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuroinflammation Modulation Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">State</td>
<td>Markers</td>
</tr>
<tr>
<td class="label">M1 (Classical)</td>
<td>CD16, CD32, iNOS, TNF-α</td>
</tr>
<tr>
<td class="label">M2a (Alternative)</td>
<td>CD206, Arg1, YM1</td>
</tr>
<tr>
<td class="label">M2b (Regulatory)</td>
<td>CD86, IL-10</td>
</tr>
<tr>
<td class="label">M2c (Acquired)</td>
<td>TGF-β</td>
</tr>
<tr>
<td class="label">DAM</td>
<td>[TREM2](/proteins/trem2-protein), CLEC7A, LPL</td>
</tr>
<tr>
<td class="label">Cytokine</td>
<td>Source</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>Microglia, [astrocytes](/entities/astrocytes)</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">IL-18</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">IL-10</td>
<td>Microglia, T cells</td>
</tr>
<tr>
<td class="label">TGF-β</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Rofecoxib</td>
<td>COX-2</td>
</tr>
<tr>
<td class="label">Naproxen</td>
<td>COX-1/2</td>
</tr>
<tr>
<td class="l

...

Neuroinflammation Modulation Therapies for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuroinflammation Modulation Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">State</td>
<td>Markers</td>
</tr>
<tr>
<td class="label">M1 (Classical)</td>
<td>CD16, CD32, iNOS, TNF-α</td>
</tr>
<tr>
<td class="label">M2a (Alternative)</td>
<td>CD206, Arg1, YM1</td>
</tr>
<tr>
<td class="label">M2b (Regulatory)</td>
<td>CD86, IL-10</td>
</tr>
<tr>
<td class="label">M2c (Acquired)</td>
<td>TGF-β</td>
</tr>
<tr>
<td class="label">DAM</td>
<td>[TREM2](/proteins/trem2-protein), CLEC7A, LPL</td>
</tr>
<tr>
<td class="label">Cytokine</td>
<td>Source</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>Microglia, [astrocytes](/entities/astrocytes)</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">IL-18</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">IL-10</td>
<td>Microglia, T cells</td>
</tr>
<tr>
<td class="label">TGF-β</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Rofecoxib</td>
<td>COX-2</td>
</tr>
<tr>
<td class="label">Naproxen</td>
<td>COX-1/2</td>
</tr>
<tr>
<td class="label">Ibuprofen</td>
<td>COX-1/2</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>Enhance protective signaling</td>
</tr>
<tr>
<td class="label">Antibodies</td>
<td>Activate TREM2</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Allosteric activation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>Olatec</td>
</tr>
<tr>
<td class="label">CRID3</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">WPIB</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Agonists</td>
</tr>
<tr>
<td class="label">CD33</td>
<td>Antagonists</td>
</tr>
<tr>
<td class="label">NLRP3</td>
<td>Inhibitors</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>Inhibitors</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Trial Result</td>
</tr>
<tr>
<td class="label">Minocycline</td>
<td>Failed (accelerated decline)</td>
</tr>
<tr>
<td class="label">CX1 antagonists</td>
<td>Negative</td>
</tr>
<tr>
<td class="label">NP001</td>
<td>Mixed</td>
</tr>
<tr>
<td class="label">Tamoxifen</td>
<td>Negative</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Interpretation</td>
</tr>
<tr>
<td class="label">YKL-40</td>
<td>Microglial activation</td>
</tr>
<tr>
<td class="label">sTREM2</td>
<td>TREM2 signaling</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Inflammasome activity</td>
</tr>
<tr>
<td class="label">[NFL](/proteins/nfl-protein)</td>
<td>Neurodegeneration</td>
</tr>
</table>

Neuroinflammation Modulation Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Neuroinflammation has emerged as a central pathological feature across virtually all neurodegenerative diseases. Unlike acute neuroinflammation, which serves protective functions, chronic neuroinflammation in conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) becomes self-perpetuating and drives progressive neuronal dysfunction and death. [@hansen2018]

The recognition that neuroinflammation is not merely a consequence but an active driver of neurodegeneration has opened therapeutic avenues targeting the immune system of the brain. Neuroinflammation modulation therapies aim to shift the inflammatory response from a damaging pro-inflammatory state to a protective or homeostatic state, potentially slowing or halting disease progression. These approaches represent one of the most active areas of neurodegeneration drug development. [@wolf2017]

The Neuroinflammatory Response in Neurodegeneration

Microglial Biology

[Microglia](/entities/microglia) are the resident immune cells of the central nervous system, comprising approximately 10-15% of brain cells. Under normal conditions, [microglia](/cell-types/microglia-neuroinflammation) continuously survey their environment, rapidly responding to any disturbance. In neurodegenerative diseases, chronic activation leads to a dysregulated inflammatory response. [@pascoal2021]

Activation States

Modern understanding recognizes multiple microglial activation states beyond the classical M1/M2 dichotomy: [@deczkowska2018]

Disease-Associated Microglia (DAM)

A distinct microglial phenotype termed Disease-Associated Microglia (DAM) has been identified in neurodegenerative conditions: [@liao2023]

[TREM2](/genes/trem2) dependence: DAM formation requires TREM2 signaling
Transcriptional signature: Distinct gene expression pattern
Phagocytic activity: Enhanced ability to clear debris and aggregates
Dual role: Can be both protective and harmful depending on context

Key Inflammatory Mediators

Cytokines

Chemokines

CCL2 (MCP-1): Monocyte recruitment
CXCL10 (IP-10): T cell recruitment
CX3CL1 (Fractalkine): Microglial modulation
CXCL12 (SDF-1): Neural stem cell migration

Complement System

The [complement system](/entities/complement-system) plays a critical role in neuroinflammation:

C1q: Initiates classical pathway, tags synapses for elimination
C3: Central complement mediator
C3a/C5a: Anaphylatoxins recruiting immune cells
C5b-9 (MAC): Membrane attack complex

Prostaglandins

COX-2: Induced in inflammation, produces PGE2
PGE2: Pro-inflammatory, affects neuronal function
Target: NSAIDs, COX-2 inhibitors

Therapeutic Approaches

Anti-inflammatory Agents

Tetracyclines

Minocycline, a tetracycline antibiotic, has shown anti-inflammatory effects:

Mechanism: Inhibits microglial activation, MMP activity
ALS trials: Mixed results in Phase 2/3
PD trials: Some cognitive benefits observed
Limitations: Antibiotic properties, GI side effects

TNF Inhibitors

Tumor necrosis factor-alpha (TNF-α) inhibitors have been explored:

Etanercept: Perispinal administration in AD pilot
Infliximab: Tested in PD
Challenge: [BBB](/entities/blood-brain-barrier) penetration
Status: Early-phase trials

NSAIDs

Non-steroidal anti-inflammatory drugs have been extensively studied:

Challenge: Timing of intervention, dose, and specific NSAID selection

Microglial Modulation

CSF1R Inhibitors

Colony-stimulating factor 1 receptor (CSF1R) is critical for microglial survival:

PLX3397 (Pexidartinib): CSF1R antagonist, depletes microglia
PLX5622: Highly specific CSF1R inhibitor
Benefits: Reduces microglial proliferation, alters phenotype
Concerns: Loss of microglial protective functions

TREM2 Modulation

TREM2 offers a nuanced therapeutic target:

CX3CR1 Modulation

The CX3CL1/CX3CR1 pathway regulates microglial-neuronal communication:

CX3CR1 antagonists: May reduce excessive microglial activation
CX3CL1 delivery: Neuroprotective in models
Genetic variants: CX3CR1 polymorphisms affect disease risk

NLRP3 Inflammasome Inhibition

The NLRP3 inflammasome is a key driver of neuroinflammation:

Inhibitors in Development

Mechanism

NLRP3 inhibition blocks:

Inflammasome assembly
Caspase-1 activation
IL-1β and IL-18 maturation
Pyroptosis (inflammatory cell death)

Metabolic Reprogramming

Microglial inflammatory phenotype is metabolically dependent:

Glycolysis Inhibition

2-DG: Glycolysis inhibitor, reduces inflammatory phenotype
FX11: Lactate dehydrogenase A inhibitor
Challenge: Systemic effects, toxicity

Ketogenic Approaches

Ketogenic diet: Shifts microglial metabolism
Beta-hydroxybutyrate: Ketone body with anti-inflammatory effects
Mechanism: Inhibits NLRP3, enhances antioxidant responses

NAD+ Augmentation

Nicotinamide riboside (NR): NAD+ precursor
NMN: NAD+ precursor
Mechanism: SIRT1 activation, anti-inflammatory

Disease-Specific Applications

Alzheimer's Disease

Neuroinflammation is particularly prominent in AD:

Pathological Drivers

[Aβ](/proteins/amyloid-beta) plaques: Activate microglia via TLRs, TREM2
[Tau](/proteins/tau) pathology: Pro-inflammatory [tau](/proteins/tau) species
APOE4: Enhanced neuroinflammatory response

Therapeutic Targets

Clinical Trials

AL002 (TREM2 agonist): Recruiting for early AD
AL003 (TREM2 antibody): Phase 1 complete
JNJ-40346527 (CSF1R inhibitor): Phase 1

Parkinson's Disease

Neuroinflammation contributes to dopaminergic neuron loss:

Inflammatory Contributors

[α-Synuclein](/proteins/alpha-synuclein): Activates microglia via TLRs
Mitochondrial dysfunction: [ROS](/entities/reactive-oxygen-species) activates inflammasome
[Gut-brain axis](/entities/gut-brain-axis): Peripheral inflammation propagation

Therapeutic Approaches

GLP-1 agonists: liraglutide, exenatide showing promise
Minocycline: Mixed results in trials
NLRP3 inhibitors: Preclinical promise

Clinical Evidence

Exenatide: Improved motor scores in PD patients
Liraglutide: Cognitive benefits observed
Infliximab: Pilot study showed motor improvement

Amyotrophic Lateral Sclerosis

ALS features prominent neuroinflammation:

Microglial Activation

SOD1 mutations: Chronic microglial activation
[TDP-43](/proteins/tdp-43) pathology: Inflammatory trigger
[C9orf72](/entities/c9orf72): Inflammatory gene variants

Trial Results

Huntington's Disease

Neuroinflammation contributes to striatal degeneration:

mHTT: Directly activates microglia
Complement: Excessive synaptic elimination
Therapeutic: NLRP3 inhibition protective in models

Biomarkers for Patient Selection

Microglial Imaging

TSPO PET: Maps microglial activation
PK11195: Classic TSPO ligand
PBR28: Second-generation ligand

Fluid Biomarkers

Challenges and Future Directions

Key Challenges

Timing: Anti-inflammatory therapy likely needs early intervention

Microglial duality: Protective functions may be lost

BBB penetration: Many agents don't reach brain

Patient selection: Biomarkers needed for responders

Emerging Approaches

Combination therapy: Multiple anti-inflammatory targets
Peripheral targeting: Modulating peripheral immune effects
Gene therapy: Targeting inflammatory pathways
Repurposing: Existing anti-inflammatory drugs

External Links

[Alzheimer's Association - Inflammation and Alzheimer's](https://www.alz.org/)
[Michael J. Fox Foundation - Inflammation in PD](https://www.michaeljfox.org/)
[ALS Association - Research](https://www.als.org/)
[ClinicalTrials.gov - Neuroinflammation](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=neuroinflammation)

Background

The study of Neuroinflammation Modulation Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Heneka MT, et al, Neuroinflammation in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25792098/)

[Hansen DV, et al, Microglia in Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29632236/)

[Wolf SA, et al, Microglia and Alzheimer's disease: inflammatory and Alzheimer's disease: inflammatory (2017)](https://pubmed.ncbi.nlm.nih.gov/28945218/)

[Pascoal TA, et al, Microglial activation and tau propagate longitudinally across the Alzheimer's disease spectrum (2021)](https://pubmed.ncbi.nlm.nih.gov/34155411/)

[Deczkowska A, et al, Disease-associated microglia: universal immune cells in neurodegenerative diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/30359610/)

[Colonna M, et al, TREM2: from innate immune sensor to Alzheimer's disease therapy (2018)](https://pubmed.ncbi.nlm.nih.gov/30026471/)

[Minter MR, et al, TREM2 and the neuroinflammation revolution (2021)](https://pubmed.ncbi.nlm.nih.gov/34239138/)

[Yang Q, et al, NLRP3 inflammasome in neurodegenerative diseases: targeting inflammation and therapeutic implications (2022)](https://pubmed.ncbi.nlm.nih.gov/35292989/)

[Broz P, et al, NLRP3 inflammasome: from innate immunity to Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32820201/)

[Haque ME, et al, Targeting microglia in Alzheimer's disease: from current understanding to therapeutic potential (2021)](https://pubmed.ncbi.nlm.nih.gov/33216032/)

[Zhang W, et al, Microglial activation in Parkinson's disease: from pathogenesis to therapeutic strategies (2022)](https://pubmed.ncbi.nlm.nih.gov/35821453/)

[Wang Q, et al, TREM2 polymorphisms in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33472919/)

[Liao B, et al, TREM2 in Alzheimer's disease: from molecular mechanisms to therapeutic potential (2023)](https://pubmed.ncbi.nlm.nih.gov/36782245/)

[Calsolaro V, et al, Neuroinflammation in amyotrophic lateral sclerosis: role of excitotoxicity (2019)](https://pubmed.ncbi.nlm.nih.gov/31679956/)

[Kwon HS, et al, Targeting neuroinflammation in Huntington's disease: a therapeutic perspective (2020)](https://pubmed.ncbi.nlm.nih.gov/32688089/)

[Liu J, et al, Neuroinflammation as a therapeutic target in Huntington's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33864786/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — 0.73 · Target: C1Q/C3
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — 0.63 · Target: CX3CR1
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins](/hypothesis/h-782b40b1) — 0.54 · Target: CX3CR1
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-neuroinflammation-modulation-therapies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-neuroinflammation-modulation-therapies
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3dcc293933e5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-neuroinflammation-modulation-therapies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

235

Outgoing

266

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neuroinflammation Modulation Therapies for Neurodegenerative Diseases

Neuroinflammation Modulation Therapies for Neurodegenerative Diseases

Introduction

Neuroinflammation Modulation Therapies for Neurodegenerative Diseases

Introduction

Overview

The Neuroinflammatory Response in Neurodegeneration

Microglial Biology

Activation States

Disease-Associated Microglia (DAM)

Key Inflammatory Mediators

Cytokines

Chemokines

Complement System

Prostaglandins

Therapeutic Approaches

Anti-inflammatory Agents

Tetracyclines

TNF Inhibitors

NSAIDs

Microglial Modulation

CSF1R Inhibitors

TREM2 Modulation

CX3CR1 Modulation

NLRP3 Inflammasome Inhibition

Inhibitors in Development

Mechanism

Metabolic Reprogramming

Glycolysis Inhibition

Ketogenic Approaches

NAD+ Augmentation

Disease-Specific Applications

Alzheimer's Disease

Pathological Drivers

Therapeutic Targets

Clinical Trials

Parkinson's Disease

Inflammatory Contributors

Therapeutic Approaches

Clinical Evidence

Amyotrophic Lateral Sclerosis

Microglial Activation

Trial Results

Huntington's Disease

Biomarkers for Patient Selection

Microglial Imaging

Fluid Biomarkers

Challenges and Future Directions

Key Challenges

Emerging Approaches

See Also

External Links

Background

References

Related Hypotheses

💬 Discussion